You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Of the 28 companies in the 360 Index, six companies' share prices increased while the share values of 22 declined month over month.
The firm now expects to complete the development work needed to request Emergency Use Authorization for the new panel.
Test makers are preparing to ramp up production of new SARS-CoV-2 assays and designated testing systems in anticipation of increased demand.
The ePlex SARS-CoV-2 Test is exclusively for use on the company's ePlex sample-to-answer system, which has a global installed base of more than 500 as of the end of 2019.
The partners' "COVID-19 task force" will invest in ePlex molecular testing platforms from GenMark Diagnostics to quadruple UCSF's testing capacity.
The firm shipped research-use-only tests last week to key customers to validate the assay design using clinical samples.
GenMark announced on Monday that it has begun shipping its first research-use-only tests for the novel coronavirus and intends to seek emergency use authorization.
More than 70 percent of ePlex analyzer placements in the fourth quarter were within labs that previously had a competitive analyzer, the firm said.
Of the 28 companies in the index, nine companies' share prices increased while the share values of 19 declined month over month.
Of the 28 companies in the index, 16 companies' share prices increased while the share values of 12 declined month over month.